Evolus, Inc. (EOLS) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

18/25

Growth 4 Margin 2 Expansion 5 Platform 3 Financial 4

latest quarter score

Earnings Reports

18
Evalyst (EOLS) Q2 2026: Portfolio Growth Bundle Drives 70% Cross-Sell, Expanding Share in Aesthetics
August 06, 2026
23
EOLS Q1 2026: Evelis Rewards Membership Surges 27%, Accelerating Platform Engagement
June 16, 2026
17
EOLS Q2 2025: Evelisse Launch Drives 10%–12% Revenue Contribution Amid Toxin Market Downturn
June 16, 2026
20
Evalyst (EOLS) Q3 2025: Evelisse Debut Drives 13% Revenue Lift, Sets Stage for Portfolio Bundling
June 16, 2026
19
Evolus (EOLS) Q4 2025: International Revenue Doubles, Portfolio Rebates Drive U.S. Share Gains
June 15, 2026
13
Evolus (EOLS) Q1 2025: Market Share Rises to 15% as Multi-Product Launch Accelerates Growth Path
July 04, 2025
Evolus (EOLS) Q4 2024: Achieves Full-Year Profitability One Year Early with 32% Revenue Growth
March 04, 2025

Browse all companies